We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Genedrive Plc | LSE:GDR | London | Ordinary Share | GB00B1VKB244 | ORD 1.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.025 | -1.35% | 1.825 | 1.75 | 1.90 | 1.85 | 1.825 | 1.85 | 1,731,938 | 09:33:46 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Coml Physical, Biologcl Resh | 55k | -5.15M | -0.0447 | -0.41 | 2.1M |
Date | Subject | Author | Discuss |
---|---|---|---|
05/5/2023 09:50 | As long as Riverfirt are involved I am staying clear.Good luck on first contract sale news | billthebank | |
05/5/2023 09:45 | Tipped somewhere? Looks like a mass of PI gamblers not II's (imo) So potential crash back and more of no upbeat rns's shortly | pugugly | |
05/5/2023 09:44 | Do you actually know if they have sold something at last? I have some in the bottom drawer but sold main part of my holding when Riverfort apppeared | billthebank | |
05/5/2023 09:39 | Not small buys taking this up. Looks like they're about to announce a big deal and im not saying anything more so dont ask. It's about time since we've all been patiently waiting since NICE. Fallen from 45p arena. Good luck | wrecktangle | |
05/5/2023 09:35 | Shorts to get burnt if they added at 20p :) | g2theary | |
05/5/2023 09:27 | 40p :D incoming ;) | g2theary | |
03/5/2023 10:32 | Dead cat bounce time Buy in for 15% | kirk 6 | |
03/5/2023 09:41 | DCB it is then :D | g2theary | |
02/5/2023 22:00 | Contract wins and higher share price would make raising easier. Just cannot see it rising for a bit until the reverse placing has run its course. Budd has a knack of throwing out "golden ticket" RNS's so who knows The issue is no guidance at all on financials from budd - just that sales will be higher. Saying its going to be higher than £20k is laughable. Could mean anything. The market has no faith in Budd, who has failed to deliver any meaningful sales ever. | thecroots | |
02/5/2023 21:51 | Ok fair point ... however the product is a unique one and works. Surly contract wins and share price increases could make a placing much easier? | g2theary | |
02/5/2023 21:49 | The Company is in ongoing dialogue still with the FDA to ascertain the requirements, and consequently the funding estimate that would be required to conduct and manage the evidence generation and submission process.Could easily be misconstrued... FDA Costs and Consulting Service Fees. How Much Does a FDA 510k Approval Cost? The vast majority of our FDA 510K clients generally spend in the range of $20,000-$30,000 to have their product or device prepared and reviewed before the actual FDA 510k submission process.Based on the above it could mean how much they need to pay ? | g2theary | |
02/5/2023 21:45 | I have no idea how they will raise. The reverse placing is generally the last roll of the dice - especially so when credit tightness is here for a while. | thecroots | |
02/5/2023 21:43 | Lol.. Says it right here!! lol As announced on 9 February 2023, NICE had preliminarily recommended that the Genedrive(R) AIHL test can be used by the NHS following the evidence review as part of their Early Value Assessment (EVA) Programme . NICE concluded that the Genedrive(R)MT-RNR1 ID Kit can quickly and accurately identify babies with the primary genetic variant, there is currently no other test available in the NHS that provides results quickly enough to inform decisions on antibiotic prescribing in emergency care, the long-term savings to the NHS associated with hearing loss and fitting cochlear implants could be substantial. Final positive NICE guidance under their Early Value Assessment programme was issued on 30 March 2023 ratifying the 9 February decision . The Directors anticipate 6-8 UK Hospitals will be in various stages from "fully operational" to "approved and beginning implementation" within 3 months post NICE final publication and anticipate 6-8 non-UK distributors will be contracted by the end of the same timeframe. The US market represents a significant opportunity for the Group's AIHL test and an FDA "pre-submission" process is currently underway however additional funding would be required to progress the FDA approval process. The Company remains engaged with the FDA in the pre-submission process | thecroots | |
02/5/2023 20:40 | Lol where Dow it say that lol | g2theary | |
02/5/2023 19:47 | Lol - You'll need a raise to get an FDA licence. David Budd said that in the latest results!!!!!! | thecroots | |
02/5/2023 17:25 | Anyway for me it's all about FDA approval here ... it's due to come within the next 6 weeks ;) DYOR Finance won't be in issue then.. share price potential multiples... I did say when I was trading these last back in balls deep covid ... they may as well use the £8M fund raise for the MT-RNR1 :) I'm only putting the profits that covid made me ... I was in here at 21p and sold out at 2.40p ;) I'll be selling out at over 100p this time ;) GLA | g2theary | |
02/5/2023 17:07 | For continual draw downs? Correct? | g2theary | |
02/5/2023 16:08 | PUT TOWER RESOURSES (TRP) ON YOUR WATCHLIST AT A ALL TIME LOW | riskyinvestor | |
02/5/2023 15:28 | They have already had the 1st 2M in early April ... correct? | g2theary | |
02/5/2023 15:11 | Blimey, people don't understand a reverse placing. 32p was just the REFERENCE price, NOT the actual price. Adjustments are made as the share price falls. Meaning more shares have to be "created" meaning more dilution, meaning more a fall. A scenario that snowballs. Hence the term death sprial. | thecroots | |
02/5/2023 15:10 | Share price says everything you need to know. And it's not great is it. | angus17 | |
02/5/2023 14:08 | Thanks for so clearly demonstrating that you don't understand death spiral finance ;-). | terminator101 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions